These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24004)

  • 21. Prolonged survival of AKR mice following allogeneic bone marrow transplantation.
    Rose WC; Bortin MM; Saltzstein EC
    Experientia; 1974 Sep; 30(9):1085-6. PubMed ID: 4153447
    [No Abstract]   [Full Text] [Related]  

  • 22. Characterization of alloimmunization-induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo.
    Truitt RL; Shih CY; Lefever AV; Tempelis LD; Andreani M; Bortin MM
    J Immunol; 1983 Oct; 131(4):2050-8. PubMed ID: 6194224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alloimmunization and adoptive immunotherapy of leukemia.
    Truitt RL; Shih CY; Rimm AA; Tempelis LD; Bortin MM
    Transplant Proc; 1981 Dec; 13(4):1910-4. PubMed ID: 6949385
    [No Abstract]   [Full Text] [Related]  

  • 24. An immunochemotherapeutic system for the treatment of a transplanted Moloney virus-induced lymphoma in mice.
    Glynn JP; Halpern BL; Fefer A
    Cancer Res; 1969 Mar; 29(3):515-20. PubMed ID: 4180092
    [No Abstract]   [Full Text] [Related]  

  • 25. The generation and specificity of cytotoxic T cells raised against syngeneic tumor cells bearing AKR/Gross murine leukemia virus antigens.
    Green WR; Nowinski RC; Henney CS
    J Exp Med; 1979 Jul; 150(1):51-66. PubMed ID: 109575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Graft-vs-leukemia and moderation of graft-vs-host reaction in transplantation therapy of viral leukemia.
    Okunewick JP; Meredith RF; Raikow RB; Brozovich BJ; Magliere K
    Exp Hematol; 1981 Aug; 9(7):754-65. PubMed ID: 7032959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alloimmunization: induction of antileukemic reactivity without modification of anti-host reactivity in H-2-compatible mice.
    Truitt RL; Bortin MM; Rimm AA
    Transplant Proc; 1980 Mar; 12(1):143-6. PubMed ID: 6966095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Graft-versus-leukemia effect in allogeneic bone marrow transplantation in mice against several radiation-induced leukemias.
    Aizawa S; Sado T; Kamisaku H; Nemoto K; Yoshida K
    Bone Marrow Transplant; 1994 Feb; 13(2):109-14. PubMed ID: 8205078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An MHC-compatible allogeneic bone marrow donor with a distinct role of T cell subsets in graft-versus-leukemia effect and lethal graft-versus-host disease.
    Aizawa S; Kamisaku H; Sado T
    Bone Marrow Transplant; 1995 Oct; 16(4):603-9. PubMed ID: 8528179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Graft versus leukemia for "cell cure" of long-passage AKR leukemia after chemoradiotherapy.
    Saltzstein EC; Glasspiegel JS; Rimm AA; Giller RH; Bortin MM
    Cancer Res; 1972 Aug; 32(8):1658-62. PubMed ID: 4402951
    [No Abstract]   [Full Text] [Related]  

  • 31. Cell surface expression of cytotoxic T lymphocyte-defined, AKR/Gross leukemia virus-associated tumor antigens by normal AKR.H-2b splenic B cells.
    Green WR
    J Immunol; 1983 Dec; 131(6):3078-84. PubMed ID: 6605998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of a Moloney lymphoma with cyclophosphamide and H-2-incompatible spleen cells.
    Fefer A
    Cancer Res; 1973 Apr; 33(4):641-4. PubMed ID: 4696464
    [No Abstract]   [Full Text] [Related]  

  • 33. Changes of the immunogenic properties of K36 lymphoma treated in vivo with 5(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC).
    Bonmassar A; Frati L; Fioretti MC; Romani L; Giampietri A; Goldin A
    Eur J Cancer (1965); 1979 Jul; 15(7):933-9. PubMed ID: 488153
    [No Abstract]   [Full Text] [Related]  

  • 34. Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to upregulate antitumor effects and downregulate antihost responses.
    Ji YH; Weiss L; Zeira M; Abdul-Hai A; Reich S; Schuger L; Slavin S
    Bone Marrow Transplant; 2003 Sep; 32(5):495-504. PubMed ID: 12942096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
    Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
    Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells.
    Berenson JR; Einstein AB; Fefer A
    J Immunol; 1975 Jul; 115(1):234-8. PubMed ID: 1080165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Graft versus leukemia. 3. Apparent independent anthost and antileukemia activity of transplanted immunocompetent cells.
    Bortin MM; Rimm AA; Saltzstein EC; Rodey GE
    Transplantation; 1973 Sep; 16(3):182-8. PubMed ID: 4147030
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of Moloney virus-induced leukemia with cyclophosphamide and specifically sensitized allogeneic cells.
    Glynn JP; Kende M
    Cancer Res; 1971 Oct; 31(10):1383-8. PubMed ID: 5095130
    [No Abstract]   [Full Text] [Related]  

  • 39. Factors related to therapeutic efficacy in adoptive chemoimmunotherapy of a Friend virus-induced lymphoma.
    Fass L; Fefer A
    Cancer Res; 1972 Nov; 32(11):2427-31. PubMed ID: 5082591
    [No Abstract]   [Full Text] [Related]  

  • 40. [Inhibition of the effect of immunocytotherapy in leukemia in mice under stress and the possibilities of its withdrawal].
    Sukhikh GT
    Biull Eksp Biol Med; 1984 Dec; 98(12):694-6. PubMed ID: 6542442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.